CN Patent

CN102482260A — 双-苯并咪唑衍生物

Assigned to Janssen R&D Ireland ULC · Expires 2012-05-30 · 14y expired

What this patent protects

式I的HCV复制的抑制剂包括其立体化学异构形式和盐、水合物、溶剂化物，其中R和R’具有如在本文中定义的含义。本发明还涉及制备所述化合物的方法、含它们的药用组合物以及它们在HCV疗法中的应用。

USPTO Abstract

式I的HCV复制的抑制剂包括其立体化学异构形式和盐、水合物、溶剂化物，其中R和R’具有如在本文中定义的含义。本发明还涉及制备所述化合物的方法、含它们的药用组合物以及它们在HCV疗法中的应用。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN102482260A
Jurisdiction: CN
Classification: —
Expires: 2012-05-30
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.